Clinical Observation of Topical Lidocaine Cream Combined With Moisturizing Cream in the Treatment of Atopic Dermatitis

NCT07067541 | Completed

• 1 other identifier: 2023-L-88
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

Twenty-five patients with atopic dermatitis applied lidocaine cream plus a moisturizer to the right limb and lidocaine cream alone to the left limb, twice daily for four weeks.

Conditions

Atopic Dermatitis

Outcome Measures

Primary Outcomes (1)

• change in SCORAD (SCORing Atopic Dermatitis) from baseline

  For each patient, a score will be obtained at baseline, after 4 weeks. The minimum score is 0 (best outcome) and the maximum score is 103 (worst outcome).

  4 weeks

Study Arms (2)

Control Group

ACTIVE COMPARATOR

Drug: Control lidocaine cream

Experimental group

EXPERIMENTAL

Drug: Experimental lidocaine cream + moisturizer cream

Interventions

Control lidocaine cream DRUG

lidocaine cream alone

Control Group

Experimental lidocaine cream + moisturizer cream DRUG

lidocaine cream + moisturizer cream

Experimental group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female patients aged 18-65 years.
• Clinical diagnosis of atopic dermatitis according to the 2020 Guidelines for the Diagnosis and Treatment of Atopic Dermatitis in China (symmetrical eczematous lesions for ≥6 months plus personal/family atopy history or elevated IgE/eosinophilia).
• Voluntarily signed informed consent form.

You may not qualify if:

• Active heart, liver, kidney, or other serious systemic illness.
• History of viral or bacterial infection within 1 month prior to enrollment.
• Immunocompromised patients or those receiving systemic immunosuppressive therapy.
• Known allergy to lidocaine, moisturizer components, or any study-related topical agents.
• Pregnant or breastfeeding women.
• Use of topical corticosteroids or calcineurin inhibitors within 2 weeks prior to enrollment.

Sponsors & Collaborators

• First Affiliated Hospital of Kunming Medical University: lead

Study Sites (1)

First Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, 650000, China

Location

MeSH Terms

Conditions

Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director

Study Record Dates

• First Submitted: July 1, 2025
• First Posted: July 16, 2025
• Study Start: October 1, 2023
• Primary Completion: January 31, 2024
• Study Completion: January 31, 2024
• Last Updated: July 16, 2025

Record last verified: 2025-07

Locations

CN (1)